• Bulletin of the Korean Chemical Society
• /
• 제31권2호
• /
• pp.281-285
• /
• 2010

Hemodialysis vascular access dysfunction (HVAD) due to the aggressive development of venous neointimal hyperplasia remains a major complication for patients with synthetic arteriovenous grafts. Paclitaxel-coated expanded polytetrafluoroethylene (ePTFE) grafts effectively prevent neointimal hyperplasia and stenosis. However, perigraft inflammation or edema can be another complication of ePTFE grafts, preventing early cannulation. Three different types of ePTFE grafts, including grafts without paclitaxel coating (control group, n = 12), grafts with paclitaxel coating at a dose density of $0.61ug/mm^2$ (low concentration group, n = 12), and grafts with paclitaxel coating at a dose density of $1.15ug/mm^2$ (high concentration group, n = 12) were placed in the backs of 12 rabbits, simultaneously. Six rabbits were euthanized after one week and the remaining six were euthanized two weeks after implantation. Perigraft inflammation, graft wall inflammation, stromal cell proliferation, blood vessel formation, tissue necrosis and edema were analyzed for the grafts in each animal. Inflammation surrounding the paclitaxel-coated grafts was significantly reduced compared to the control group. Stromal cell layers were detected at the interface between the graft and the surrounding tissue in the control group, infiltrated into the graft interstices, and differentiated into myofibroblasts for graft healing. Paclitaxel-coated grafts inhibited stromal cell proliferation and infiltration into the graft wall. Tissue necrosis and edema were not detected in either of the paclitaxel-coated graft groups.

• KSBB Journal
• /
• 제14권1호
• /
• pp.17-23
• /
• 1999

초임계 이산화탄소 크로마토그래피 방법에 의한 paclutaxel baccatm III, 7-epn-10-deacetyltaxol.cephalomanme, 10-deacetyltaxol의 분리에서 초임계 유체의 압력, 온도 및 이동상의 조성이 미치는 영향을 연구하였다. Pachaxel, 10-deacetylbaccatin III, 10-deacetyltaxol은 압력, 온도, 이동상의 조성 변화에 의하여 우수한 분리 결과를 얻을 수 있었다. Pacltaxel 의 경우 압력 275kg/$\textrm{cm}^2$,온도 $40^{\circ}C$, 이동상 조성을 초기 20분간 초임계 이산화탄소와 보조용매인 메탄올을 각각 3.9~3.6mL/min, 0.1~0.4mL/min의 gradienl조건으로 하였을 때 가장 우수한 분리능을 보였다. Baccatin III, caphalomamine, 7-epn-10-deacetyltaxol의 경우에는 낮은 분리능을 보였다. 주목 분말 시료로부터 paclitaxel 을 정제할 때 on-linc coupled SFE/SFC장치를 이용하여 추출 정제 공정을 단순화하였다. 초임계이산화탄소를 용매로하여 추출, 1차 정제 및 크로마토그래픽 정제 단계를 연속적으로 거쳐 38%수율로 95%paclitazel을 얻을 수 있었다.

• 한국미생물·생명공학회지
• /
• 제41권2호
• /
• pp.176-182
• /
• 2013

바이오매스 유래 항암물질 paclitaxel 정제를 위하여, 물리적 특성이 다른 메조기공 알루미나 흡착제를 제조하여 흡착제 처리 효과를 조사하였다. 알루미나의 물리적 특성 중 표면적과 기공부피 보다는 기공크기(기공지름)이 흡착제 처리효과에 많은 영향을 미쳤다. 특히 적절한 기공크기(기공지름: 10.8 nm)에서 식물유래 타르 및 왁스 성분을 포함한 불순물을 제거하는데 가장 효과적이었다. 일정한 기공크기에서 흡착제의 표면적은 paclitaxel 순도뿐만 아니라 수율에 많은 영향을 미치며 흡착제의 표면적이 증가할수록 paclitaxel과 불순물(바이오매스 유래 타르 및 왁스 성분 포함)의 흡착 정도는 증가하였다. 이러한 불순물 제거 효과는 흡착제 처리 후 흡착제를 메탄올로 세척하여 HPLC로 분석한 결과와 흡착제에 붙은 유기물의 TGA 정량 분석 결과로도 확인할 수 있었다.

• KSBB Journal
• /
• 제22권4호
• /
• pp.197-200
• /
• 2007

식물세포배양으로부터 paclitaxel을 효율적으로 대량추출하기 위한 추출액의 여과 및 농축 조건을 최적화하였다. 메탄올을 이용한 biomass 추출물을 여과할 경우, biomass 대비 6% (w/w) 여과보조제인 규조토를 첨가할 경우 여과시간 단축에 가장 효과적임을 알 수 있었다. 규조토 6% (w/w) 첨가를 통하여 1회 biomass 추출물 여과 시 4.2%, 2회 추출물 여과 시 30.3%, 3회 추출물 여과 시 22.8%, 4회 추출물 여과 시 19.0%의 여과시간 단축 효과를 각각 얻을 수 있었다. 여과액의 농축은 paclitaxel 순도 및 수율을 고려할 때 rotary evaporator의 bath 온도를 50$^{\circ}C$ 이하로 운전하는 것이 바람직하였으며, 이때 농축액의 온도는 증발잠열 때문에 실제 bath의 온도보다는 상당히 낮음을 알 수 있었다. 또한 여과액의 농축 완료 시점은 paclitaxel 순도, 수율, 농축시간, 액-액 추출에서의 상 분리 시간 등을 고려할 때 농축액의 비중이 0.95에서 종료하는 것이 가장 적당함을 알 수 있었다.

• Bulletin of the Korean Chemical Society
• /
• 제29권2호
• /
• pp.422-426
• /
• 2008

Hemodialysis graft coated with paclitaxel prevents stenosis; however, large initial burst release of paclitaxel causes many negative effects such as drug toxicity and inefficient drug loss. Therefore we developed and tested a novel coating method, double dipping, to provide controlled and sustained release of paclitaxel locally. Expanded polytetrafluoroethylene (ePTFE) grafts were dipped twice into a solution of several different paclitaxel concentrations. In vitro release tests of the double dipping method showed that early burst release could be somewhat retarded and followed by sustained release for a long time. We observed the effect of paclitaxel coating by double dipping in porcine model of arterio-venous (AV) grafts between the common carotid artery and the external jugular vein. 12 weeks after constructing AV grafts, cross sections of the graft venous anastomosis were obtained and analyzed. Paclitaxel coated ePTFE grafts by double dipping were observed to prevent neointimal hyperplasia and therefore reduced stenosis of the arteriovenous hemodialysis grafts, especially at the graft venous anastomosis sites. Our results demonstrate that second dipping of ePTFE graft, which was already coated once with paclitaxel, washes off the drug on a surface of the graft and affects the ratio of paclitaxel on the surface to that of the inner space, possibly by diffusion: thus the early burst of drug can be somewhat reduced.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권14호
• /
• pp.5741-5745
• /
• 2014

Purpose: To study the expression of insulin-like growth factor binding proteins (IGFBPs) in paclitaxel-treated gastric cancer SGC-7901 cells, and to further investigate underlying mechanisms. Materials and Methods: Real time PCR and Western blot assays were applied to detect the mRNA and protein expression of IGFBP-2, -3 and -5 after paclitaxel (10 nM) treatment of SGC-7901 cells. In addition IGFBP-3 expression was silenced by RNA interference to determine effects. Cell viability was determined by MTT assay. Cell cycling and apoptosis were assessed by flow cytometry. Results: Compared to the control group, only IGFBP-3 expression was elevated significantly after paclitaxel (10 nM) treatment (p<0.05). Paclitaxel treatment caused cell cycle arrest and apoptosis via downregulating Bcl-2 expression. However, the effect could be abrogated by IGFBP-3 silencing. Conclusions: IGFBP-3 exhibits anti-apoptotic effects on paclitaxel-treated SGC-7901 cells via elevating Bcl-2 expression.

• KSBB Journal
• /
• 제24권2호
• /
• pp.212-215
• /
• 2009

본 연구에서는 식물세포배양으로부터 항암물질 paclitaxel을 고 순도, 고 수율로 분리 가능한 액-액 추출 공정에서의 주요 공정 변수들을 최적화 하였다. 액-액 추출을 위한 최적의 유기용매 (methylene chloride) 첨가량, 추출횟수, 혼합시간, 정체시간은 각각 0.28 (v/v), 3 (times), 30 min, and 40 min 임을 알 수 있었다. 액-액 추출 공정은 특히 메탄올을 이용한 biomass 추출물에 포함되어 있는 다량의 극성불순물을 제거하는데 매우 효과적이었다. 또한 액-액 추출 후 농축조건으로는 후속공정에서의 높은 순도의 paclitaxel 뿐만 아니라 작업의 용이성 측면에서 액-액 추출액을 rotary evaporator로 완전히 농축하는 것이 가장 바람직함을 알 수 있었다.

• 한국독성학회:학술대회논문집
• /
• 한국독성학회 2002년도 Molecular and Cellular Response to Toxic Substances
• /
• pp.136-136
• /
• 2002

Experiments were carried out to determine the role of Raf-1 kinase in the development of drug resistance and apoptosis induced by paclitaxel. In the present study, paclitaxel sensitivity, Raf-1 activity and MAPKs activation were compared in 2 cell lines: parental human breast cancer cells and its drug resistant variant (MCF-7/Adr) cells.(omitted)

• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2-2
• /
• pp.240.1-240.1
• /
• 2003

The purpose of this study was to investigate the effect of nifedipine (10 mg/kg) on the pharmacokinetic parameters and the bioavailability of paclitaxel (50 mg/kg) orally coadministered and pretreated in rats. The plasma concentration of paclitaxel in combination with nifedipine was significantly (p<0.05 at 10 mg/kg coadmin., p<0.01 at pretreat.) increased compared to that of control, from 2 hr to 24 hr. Area under the plasma concentration-time curve (AUC) of paclitaxel with nifedipine was significantly (p＜0.05 at 10 mg/kg coadmin., p＜0.01 at pretreat.) higher than that of control (omitted)

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권4호
• /
• pp.1699-1702
• /
• 2014

Objective: To evaluate clinical efficacy of a dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung (NSCLC). Methods: Patients with locally advanced NSCLC were treated with conventional fractionated radiotherapy or three dimensional conformal radiotherapy (3 DCRT), concurrently with a dose escalating schedule of paclitaxel. All patients were divided into three groups, A with paclitaxel $30mg/m^2$, B with paclitaxel $60mg/m^2$ and C with paclitaxel $90mg/m^2$. Paclitaxel was repeated every week for a total of 4 or 6 weeks. Results: Among 109 patients, response rates were 68.8%, 71.1% and 71.8% (p>0.05) for group A (n=32), B (n=38), and C (n=39) respectively. Accordingly, disease control rates were 81.3%, 81.6% and 82.1% (p>0.05). Progression-free survival time was $8.0{\pm}5.0$ months, $11.6{\pm}6.1$ months, and $14.8{\pm}7.9$ months (p<0.05), respectively. Overall survival time was $15.4{\pm}7.6$ months, $18.2{\pm}8.0$ months, and $22.0{\pm}7.6$ months (p<0.05), one-year survival rates were 62.5%, 73.1% and 90.0% (p>0.05) and two-year survival rates were 31.3%, 38.5% and 50.0% (p<0.05). Main side-effects were bone marrow suppression, radiation related esophagitis and gastrointestinal reaction. Conclusion: In treating patients with NSCLC, concurrent chemoradiotherapy with paclitaxel improves early response compared with conventional fractionated radiotherapy or 3 DCRT. The survival rate was improved with the addition of paclitaxel, but there was an increase in adverse reactions when the dose of paclitaxel was increased.